Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2024

Open Access 01-12-2024 | Review

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

Authors: Yamei Hu, Zigang Dong, Kangdong Liu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a transcriptional factor involved in almost all cancer hallmark features including tumor proliferation, metastasis, angiogenesis, immunosuppression, tumor inflammation, metabolism reprogramming, drug resistance, cancer stemness. Therefore, STAT3 has become a promising therapeutic target in a wide range of cancers. This review focuses on the up-to-date knowledge of STAT3 signaling in cancer. We summarize both the positive and negative modulators of STAT3 together with the cancer hallmarks involving activities regulated by STAT3 and highlight its extremely sophisticated regulation on immunosuppression in tumor microenvironment and metabolic reprogramming. Direct and indirect inhibitors of STAT3 in preclinical and clinical studies also have been summarized and discussed. Additionally, we highlight and propose new strategies of targeting STAT3 and STAT3-based combinations with established chemotherapy, targeted therapy, immunotherapy and combination therapy. These efforts may provide new perspectives for STAT3-based target therapy in cancer.
Appendix
Available only for authorised users
Literature
1.
2.
Aigner P, Just V, Stoiber D. STAT3 isoforms: alternative fates in cancer? Cytokine. 2019;118:27–34.PubMedCrossRef
3.
Hevehan DL, Miller WM, Papoutsakis ET. Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood. 2002;99:1627–37.PubMedCrossRef
4.
Kato T, Sakamoto E, Kutsuna H, Kimura-Eto A, Hato F, Kitagawa S. Proteolytic conversion of STAT3alpha to STAT3gamma in human neutrophils: role of granule-derived serine proteases. J Biol Chem. 2004;279:31076–80.PubMedCrossRef
5.
Chakraborty A, Tweardy DJ. Granulocyte colony-stimulating factor activates a 72-kDa isoform of STAT3 in human neutrophils. J Leukoc Biol. 1998;64:675–80.PubMedCrossRef
6.
Mehta A, Ramachandra CJA, Chitre A, Singh P, Lua CH, Shim W. Acetylated signal transducer and activator of transcription 3 functions as molecular adaptor independent of transcriptional activity during human Cardiogenesis. Stem Cells. 2017;35:2129–37.PubMedCrossRef
7.
Diallo M, Herrera F. The role of understudied post-translational modifications for the behavior and function of signal transducer and activator of transcription 3. FEBS J. 2022;289:6235–55.PubMedCrossRef
8.
Wang X, Guo J, Che X, Jia R. PCBP1 inhibits the expression of oncogenic STAT3 isoform by targeting alternative splicing of STAT3 exon 23. Int J Biol Sci. 2019;15:1177–86.PubMedPubMedCentralCrossRef
9.
Aigner P, Mizutani T, Horvath J, Eder T, Heber S, Lind K, et al. STAT3beta is a tumor suppressor in acute myeloid leukemia. Blood Adv. 2019;3:1989–2002.PubMedPubMedCentralCrossRef
10.
Zhang HX, Yang PL, Li EM, Xu LY. STAT3beta, a distinct isoform from STAT3. Int J Biochem Cell Biol. 2019;110:130–9.PubMedCrossRef
11.
Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med. 2010;16:1421–8.PubMedPubMedCentralCrossRef
12.
13.
Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 2004;23:4921–9.PubMedCrossRef
14.
Teng TS, Lin B, Manser E, Ng DC, Cao X. Stat3 promotes directional cell migration by regulating Rac1 activity via its activator betaPIX. J Cell Sci. 2009;122:4150–9.PubMedCrossRef
15.
Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000–8.PubMedCrossRef
16.
Huynh J, Chand A, Gough D, Ernst M. Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer. 2019;19:82–96.PubMedCrossRef
17.
18.
19.
Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009;27:2383–92.PubMedCrossRef
20.
Zhang C, Yue C, Herrmann A, Song J, Egelston C, Wang T, et al. STAT3 activation-induced fatty acid oxidation in CD8+ T effector cells is critical for obesity-promoted breast tumor growth. Cell Metab. 2020;31(148–161):e145.
21.
Cheng CC, Shi LH, Wang XJ, Wang SX, Wan XQ, Liu SR, et al. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Int J Oncol. 2018;53:339–48.PubMed
22.
Cheng Z, Lei Z, Yang P, Si A, Xiang D, Tang X, et al. Exosome-transmitted p120-catenin suppresses hepatocellular carcinoma progression via STAT3 pathways. Mol Carcinog. 2019;58:1389–99.PubMedCrossRef
23.
Courapied S, Sellier H, de Carne TS, Vigneron A, Bernard AC, Gamelin E, et al. The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem. 2010;285:26765–78.PubMedPubMedCentralCrossRef
24.
Waitkus MS, Chandrasekharan UM, Willard B, Tee TL, Hsieh JK, Przybycin CG, et al. Signal integration and gene induction by a functionally distinct STAT3 phosphoform. Mol Cell Biol. 2014;34:1800–11.PubMedPubMedCentralCrossRef
25.
26.
Zhang Q, Raje V, Yakovlev VA, Yacoub A, Szczepanek K, Meier J, et al. Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. J Biol Chem. 2013;288:31280–8.PubMedPubMedCentralCrossRef
27.
Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007;21:1396–408.PubMedPubMedCentralCrossRef
28.
Nishimoto A, Kugimiya N, Hosoyama T, Enoki T, Li TS, Hamano K. JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells. Biochem Biophys Res Commun. 2013;438:513–8.PubMedCrossRef
29.
Jhaveri K, Teplinsky E, Silvera D, Valeta-Magara A, Arju R, Giashuddin S, et al. Hyperactivated mTOR and JAK2/STAT3 pathways: molecular drivers and potential therapeutic targets of inflammatory and invasive ductal breast cancers after Neoadjuvant chemotherapy. Clin Breast Cancer. 2016;16(113–122):e111.
30.
Shukla S, Shishodia G, Mahata S, Hedau S, Pandey A, Bhambhani S, et al. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Mol Cancer. 2010;9:282.PubMedPubMedCentralCrossRef
31.
Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res. 2011;17:1452–62.PubMedPubMedCentralCrossRef
32.
Huang C, Huang R, Chang W, Jiang T, Huang K, Cao J, et al. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma. 2012;59:52–61.PubMedCrossRef
33.
Hu Y, Liu F, Jia X, Wang P, Gu T, Liu H, et al. Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3. Oncogene. 2021;40:3942–58.PubMedCrossRef
34.
Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res : Off J Am Assoc Cancer Res. 2005;11:8288–94.CrossRef
35.
Li H, Qian Y, Wang X, Pi R, Zhao X, Wei X. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden. Cell Prolif. 2020;53:e12719.PubMedCrossRef
36.
Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK− anaplastic large cell lymphoma. Clin Cancer Res. 2003;9:3692–9.PubMed
37.
Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117:5701–9.PubMedPubMedCentralCrossRef
38.
Sayed D, Badrawy H, Gaber N, Khalaf MR. P-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy. Leuk Res. 2014;38:243–50.PubMedCrossRef
39.
40.
Shi S, Ma HY, Zhang ZG. Clinicopathological and prognostic value of STAT3/p-STAT3 in cervical cancer: a meta and bioinformatics analysis. Pathol Res Pract. 2021;227:153624.PubMedCrossRef
41.
Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16:585–601.PubMedCrossRef
42.
Natani S, Dhople VM, Parveen A, Sruthi KK, Khilar P, Bhukya S, et al. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells. Biochim Biophys Acta Mol Cell Res. 2021;1868:119085.PubMedCrossRef
43.
Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate. 2000;42:186–95.PubMedCrossRef
44.
Zheng L, Jia X, Zhang C, Wang D, Cao Z, Wang J, et al. Angiotensin II in atrial structural remodeling: the role of Ang II/JAK/STAT3 signaling pathway. Am J Transl Res. 2015;7:1021.PubMedPubMedCentral
45.
Liu Y, Deng J, Wang L, Lee H, Armstrong B, Scuto A, et al. S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood. 2012;120:1458–65.PubMedPubMedCentralCrossRef
46.
Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736–46.PubMedCrossRef
47.
Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012;22:466–78.PubMedCrossRef
48.
Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu K, et al. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer. 2010;10:415.PubMedPubMedCentralCrossRef
49.
McCall KD, Harii N, Lewis CJ, Malgor R, Kim WB, Saji M, et al. High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology. 2007;148:4226–37.PubMedCrossRef
50.
Herrmann A, Cherryholmes G, Schroeder A, Phallen J, Alizadeh D, Xin H, et al. TLR9 is critical for glioma stem cell maintenance and targeting. Cancer Res. 2014;74:5218–28.PubMedPubMedCentralCrossRef
51.
Siveen KS, Prabhu KS, Achkar IW, Kuttikrishnan S, Shyam S, Khan AQ, et al. Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products. Mol Cancer. 2018;17:31.PubMedPubMedCentralCrossRef
52.
53.
Ortiz MA, Mikhailova T, Li X, Porter BA, Bah A, Kotula L. Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition. Cell Commun Signal. 2021;19:67.PubMedPubMedCentralCrossRef
54.
Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, et al. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005;24:3110–20.PubMedCrossRef
55.
Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia. 2015;29:586–97.PubMedCrossRef
56.
Coppo P, Flamant S, De Mas V, Jarrier P, Guillier M, Bonnet ML, et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol. 2006;134:171–9.PubMedCrossRef
57.
Gkouveris I, Nikitakis N, Karanikou M, Rassidakis G, Sklavounou A. Erk1/2 activation and modulation of STAT3 signaling in oral cancer. Oncol Rep. 2014;32:2175–82.PubMedCrossRef
58.
Zhang X, Yang J, Bian Z, Shi D, Cao Z. Long noncoding RNA DANCR promotes nasopharyngeal carcinoma progression by interacting with STAT3, enhancing IL-6/JAK1/STAT3 signaling. Biomed Pharmacother. 2019;113:108713.PubMedCrossRef
59.
Zhu X, Liu L, Wang Y, Cong J, Lin Z, Wang Y, et al. lncRNA MIAT/HMGB1 Axis is involved in cisplatin resistance via regulating IL6-mediated activation of the JAK2/STAT3 pathway in nasopharyngeal carcinoma. Front Oncol. 2021;11:651693.PubMedPubMedCentralCrossRef
60.
Liang C, Zhao T, Li H, He F, Zhao X, Zhang Y, et al. Long non-coding RNA ITIH4-AS1 accelerates the proliferation and metastasis of colorectal Cancer by activating JAK/STAT3 signaling. Mol Ther Nucleic Acids. 2019;18:183–93.PubMedPubMedCentralCrossRef
61.
Zhao J, Du P, Cui P, Qin Y, Hu C, Wu J, et al. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene. 2018;37:4094–109.PubMedCrossRef
62.
Yan Z, Hong S, Song Y, Bi M. microR-4449 promotes colorectal Cancer cell proliferation via regulation of SOCS3 and activation of STAT3 signaling. Cancer Manag Res. 2021;13:3029–39.PubMedPubMedCentralCrossRef
63.
Xiao Y, Huang W, Huang H, Wang L, Wang M, Zhang T, et al. miR-182-5p and miR-96-5p target PIAS1 and mediate the negative feedback regulatory loop between PIAS1 and STAT3 in endometrial Cancer. DNA Cell Biol. 2021;40:618–28.PubMedCrossRef
64.
Ye T, Zhong L, Ye X, Liu J, Li L, Yi H. miR-221-3p and miR-222-3p regulate the SOCS3/STAT3 signaling pathway to downregulate the expression of NIS and reduce radiosensitivity in thyroid cancer. Exp Ther Med. 2021;21:652.PubMedPubMedCentralCrossRef
65.
Muhammad N, Bhattacharya S, Steele R, Ray RB. Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget. 2016;7:58595–605.PubMedPubMedCentralCrossRef
66.
67.
Gao X, Xia X, Li F, Zhang M, Zhou H, Wu X, et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling. Nat Cell Biol. 2021;23:278–91.PubMedCrossRef
68.
Mao W, Huang X, Wang L, Zhang Z, Liu M, Li Y, et al. Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression. J Exp Clin Cancer Res. 2019;38:1–14.CrossRef
69.
Ray S, Boldogh I, Brasier AR. STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology. 2005;129:1616–32.PubMedCrossRef
70.
Hou T, Ray S, Lee C, Brasier AR. The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. J Biol Chem. 2008;283:30725–34.PubMedPubMedCentralCrossRef
71.
Xu YS, Liang JJ, Wang Y, Zhao XJ, Xu L, Xu YY, et al. STAT3 undergoes acetylation-dependent mitochondrial translocation to regulate pyruvate metabolism. Sci Rep. 2016;6:39517.PubMedPubMedCentralCrossRef
72.
Dasgupta M, Dermawan JK, Willard B, Stark GR. STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc Natl Acad Sci U S A. 2015;112:3985–90.PubMedPubMedCentralCrossRef
73.
Zhang M, Zhou L, Xu Y, Yang M, Xu Y, Komaniecki GP, et al. A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis. Nature. 2020;586:434–9.PubMedPubMedCentralCrossRef
74.
75.
Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 2001;19:378–87.PubMedCrossRef
76.
Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19:456–69.PubMedCrossRef
77.
Chevrier M, Bobbala D, Villalobos-Hernandez A, Khan MG, Ramanathan S, Saucier C, et al. Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer. BMC Cancer. 2017;17:157.PubMedPubMedCentralCrossRef
78.
McFarland BC, Gray GK, Nozell SE, Hong SW, Benveniste EN. Activation of the NF-kappaB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. Mol Cancer Res : MCR. 2013;11:494–505.PubMedCrossRef
79.
Cabrera-Galván JJ, Araujo E, de Mirecki-Garrido M, Pérez-Rodríguez D, Guerra B, Aranda-Tavío H, et al. SOCS2 protects against chemical-induced hepatocellular carcinoma progression by modulating inflammation and cell proliferation in the liver. Biomed Pharmacother. 2023;157:114060.PubMedCrossRef
80.
Sasi W, Jiang WG, Sharma A, Mokbel K. Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer. 2010;10:178.PubMedPubMedCentralCrossRef
81.
Yoon S, Yi YS, Kim SS, Kim JH, Park WS, Nam SW. SOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues. Tumour Biol : J Int Soc Oncodev Biol Med. 2012;33:215–21.CrossRef
82.
Zhu JG, Dai QS, Han ZD, He HC, Mo RJ, Chen G, et al. Expression of SOCSs in human prostate cancer and their association in prognosis. Mol Cell Biochem. 2013;381:51–9.PubMedCrossRef
83.
Letellier E, Schmitz M, Baig K, Beaume N, Schwartz C, Frasquilho S, et al. Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer. Br J Cancer. 2014;111:726–35.PubMedPubMedCentralCrossRef
84.
Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997;278:1803–5.PubMedCrossRef
85.
Kim M, Morales LD, Jang IS, Cho YY, Kim DJ. Protein tyrosine phosphatases as potential regulators of STAT3 signaling. Int J Mol Sci. 2018;19.
86.
Wang Y, Wu S, Zhu X, Zhang L, Deng J, Li F, et al. LncRNA-encoded polypeptide ASRPS inhibits triple-negative breast cancer angiogenesis. J Exp Med. 2020;217.
87.
Jin S, Yang X, Li J, Yang W, Ma H, Zhang Z. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma. Mol Cancer. 2019;18:38.PubMedPubMedCentralCrossRef
88.
Wang S, Wu G, Han Y, Song P, Chen J, Wu Y, et al. miR-124 regulates STAT3-mediated cell proliferation, migration and apoptosis in bladder cancer. Oncol Lett. 2018;16:5875–81.PubMedPubMedCentral
89.
Yang L, Zhang S, Guo K, Huang H, Qi S, Yao J, et al. miR-125a restrains cell migration and invasion by targeting STAT3 in gastric cancer cells. OncoTargets Ther. 2019;12:205–15.CrossRef
90.
Yang F, Wang H, Yan B, Li T, Min L, Chen E, et al. Decreased level of miR-1301 promotes colorectal cancer progression via activation of STAT3 pathway. Biol Chem. 2021;402:805–13.PubMedCrossRef
91.
Liang Y, Li S, Tang L. MicroRNA 320, an anti-oncogene target miRNA for Cancer therapy. Biomedicines. 2021;9.
92.
Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology (Baltimore, Md). 2013;58:158–70.PubMedCrossRef
93.
Zhang J, Jia J, Zhao L, Li X, Xie Q, Chen X, et al. Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell. Mol Carcinog. 2016;55:732–42.PubMedCrossRef
94.
Ma L, Huang C, Wang XJ, Xin DE, Wang LS, Zou QC, et al. Lysyl oxidase 3 is a dual-specificity enzyme involved in STAT3 Deacetylation and Deacetylimination modulation. Mol Cell. 2017;65:296–309.PubMedCrossRef
95.
Yang J, Huang J, Dasgupta M, Sears N, Miyagi M, Wang B, et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A. 2010;107:21499–504.PubMedPubMedCentralCrossRef
96.
Lin W, Luo J, Sun Y, Lin C, Li G, Niu Y, et al. ASC-J9((R)) suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3. Cancer Lett. 2018;425:21–30.PubMedCrossRef
97.
Butturini E, Darra E, Chiavegato G, Cellini B, Cozzolino F, Monti M, et al. S-Glutathionylation at Cys328 and Cys542 impairs STAT3 phosphorylation. ACS Chem Biol. 2014;9:1885–93.PubMedCrossRef
98.
Buettner R, Corzano R, Rashid R, Lin J, Senthil M, Hedvat M, et al. Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development. ACS Chem Biol. 2011;6:432–43.PubMedPubMedCentralCrossRef
99.
Kim J, Won JS, Singh AK, Sharma AK, Singh I. STAT3 regulation by S-nitrosylation: implication for inflammatory disease. Antioxid Redox Signal. 2014;20:2514–27.PubMedPubMedCentralCrossRef
100.
Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, et al. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene. 1999;18:1023–32.PubMedCrossRef
101.
Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity. 1999;11:709–19.PubMedCrossRef
102.
Sun J, Du Y, Song Q, Nan J, Guan P, Guo J, et al. E2F is required for STAT3-mediated upregulation of cyclin B1 and Cdc2 expressions and contributes to G2-M phase transition. Acta Biochim Biophys Sin. 2019;51:313–22.PubMedCrossRef
103.
Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol. 2007;20:416–26.PubMedCrossRef
104.
Verma RP, Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem. 2007;15:2223–68.PubMedCrossRef
105.
Zugowski C, Lieder F, Muller A, Gasch J, Corvinus FM, Moriggl R, et al. STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol Chem. 2011;392:449–59.PubMedCrossRef
106.
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927–39.PubMedCrossRef
107.
Xiong H, Hong J, Du W, Lin YW, Ren LL, Wang YC, et al. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem. 2012;287:5819–32.PubMedCrossRef
108.
Wu Y, Diab I, Zhang X, Izmailova ES, Zehner ZE. Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89. Oncogene. 2004;23:168–78.PubMedCrossRef
109.
Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10:48–54.PubMedCrossRef
110.
Huang YH, Wu MP, Pan SC, Su WC, Chen YW, Wu LW. STAT1 activation by venous malformations mutant Tie2-R849W antagonizes VEGF-A-mediated angiogenic response partly via reduced bFGF production. Angiogenesis. 2013;16:207–22.PubMedCrossRef
111.
Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41–51.PubMedCrossRef
112.
Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, et al. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci. 2016;107:1696–704.PubMedPubMedCentralCrossRef
113.
Wang J, Wei W, Tang Q, Lu L, Luo Z, Li W, et al. Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti-lag-3 via reducing FGL1 expression. Cancer Med. 2020;9:7125–36.PubMedPubMedCentralCrossRef
114.
115.
116.
Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol. 2004;172:464–74.PubMedCrossRef
117.
Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120:457–71.PubMedPubMedCentral
118.
119.
Irey EA, Lassiter CM, Brady NJ, Chuntova P, Wang Y, Knutson TP, et al. JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors. Proc Natl Acad Sci U S A. 2019;116:12442–51.PubMedPubMedCentralCrossRef
120.
Shukla SK, Markov SD, Attri KS, Vernucci E, King RJ, Dasgupta A, et al. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Cancer Lett. 2020;484:29–39.PubMedPubMedCentralCrossRef
121.
Fu XL, Duan W, Su CY, Mao FY, Lv YP, Teng YS, et al. Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression. Cancer Immunol Immunother. 2017;66:1597–608.PubMedCrossRef
122.
Andersen MN, Etzerodt A, Graversen JH, Holthof LC, Moestrup SK, Hokland M, et al. STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes. Cancer Immunol Immunother. 2019;68:489–502.PubMedCrossRef
123.
Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11:1314–21.PubMedCrossRef
124.
Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest. 2010;120:1151–64.PubMedPubMedCentralCrossRef
125.
Cheng Y, Li H, Deng Y, Tai Y, Zeng K, Zhang Y, et al. Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 2018;9:422.PubMedPubMedCentralCrossRef
126.
Li S, Cong X, Gao H, Lan X, Li Z, Wang W, et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. J Exp Clin Cancer Res. 2019;38:1–13.CrossRef
127.
Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, et al. STAT3 modulation of regulatory T cells in response to radiation therapy in head and neck Cancer. J Natl Cancer Inst. 2019;111:1339–49.PubMedPubMedCentralCrossRef
128.
Zhu X-w, Zhu H-z, Zhu Y-q, Feng M-h, Qi J, Chen Z-f. Foxp3 expression in CD4+ CD25+ Foxp3+ regulatory T cells promotes development of colorectal cancer by inhibiting tumor immunity. J Huazhong Univ Sci Technol [Med Sci]. 2016;36:677–82.CrossRef
129.
Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303–10.PubMedPubMedCentralCrossRef
130.
Yue C, Shen S, Deng J, Priceman SJ, Li W, Huang A, et al. STAT3 in CD8+ T cells inhibits their tumor accumulation by downregulating CXCR3/CXCL10 Axis. Cancer Immunol Res. 2015;3:864–70.PubMedPubMedCentralCrossRef
131.
Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 2010;70:9599–610.PubMedPubMedCentralCrossRef
132.
Han Q, Wang Y, Pang M, Zhang J. STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC. J Exp Clin Cancer Res. 2017;36:1–11.CrossRef
133.
Wang X, Xin W, Zhang H, Zhang F, Gao M, Yuan L, et al. Aberrant expression of p-STAT3 in peripheral blood CD4+ and CD8+ T cells related to hepatocellular carcinoma development. Mol Med Rep. 2014;10:2649–56.PubMedCrossRef
134.
135.
136.
Zhang C, Xin H, Zhang W, Yazaki PJ, Zhang Z, Le K, et al. CD5 binds to Interleukin-6 and induces a feed-forward loop with the transcription factor STAT3 in B cells to promote Cancer. Immunity. 2016;44:913–23.PubMedPubMedCentralCrossRef
137.
138.
139.
Yang R, Lirussi D, Thornton TM, Jelley-Gibbs DM, Diehl SA, Case LK, et al. Mitochondrial Ca(2)(+) and membrane potential, an alternative pathway for Interleukin 6 to regulate CD4 cell effector function. Elife. 2015;4.
140.
Wang T, Fahrmann JF, Lee H, Li Y-J, Tripathi SC, Yue C, et al. JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab. 2018;27(136–150):e135.
141.
Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022;139:584–96.PubMedPubMedCentralCrossRef
142.
Mantel C, Messina-Graham S, Moh A, Cooper S, Hangoc G, Fu XY, et al. Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype. Blood. 2012;120:2589–99.PubMedPubMedCentralCrossRef
143.
Tammineni P, Anugula C, Mohammed F, Anjaneyulu M, Larner AC, Sepuri NB. The import of the transcription factor STAT3 into mitochondria depends on GRIM-19, a component of the electron transport chain. J Biol Chem. 2013;288:4723–32.PubMedCrossRef
144.
Valenca-Pereira F, Fang Q, Marie IJ, Giddings EL, Fortner KA, Yang R, et al. IL-6 enhances CD4 cell motility by sustaining mitochondrial ca(2+) through the noncanonical STAT3 pathway. Proc Natl Acad Sci U S A. 2021;118.
145.
Yang R, Masters AR, Fortner KA, Champagne DP, Yanguas-Casas N, Silberger DJ, et al. IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21-producing B helper CD8+ T cells. J Exp Med. 2016;213:2281–91.PubMedPubMedCentralCrossRef
146.
Poholek CH, Raphael I, Wu D, Revu S, Rittenhouse N, Uche UU, et al. Noncanonical STAT3 activity sustains pathogenic Th17 proliferation and cytokine response to antigen. J Exp Med. 2020;217.
147.
Shin B, Benavides GA, Geng J, Koralov SB, Hu H, Darley-Usmar VM, et al. Mitochondrial oxidative phosphorylation regulates the fate decision between pathogenic Th17 and regulatory T cells. Cell Rep. 2020;30:1898–909.PubMedPubMedCentralCrossRef
148.
Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D’Angeli L, Bartoli A, et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY). 2010;2:823–42.PubMedCrossRef
149.
Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S, et al. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J. 2012;31:1985–98.PubMedPubMedCentralCrossRef
150.
Qin X, Lin L, Cao L, Zhang X, Song X, Hao J, et al. Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis. Sci Rep. 2017;7:45305.PubMedPubMedCentralCrossRef
151.
Bi YH, Han WQ, Li RF, Wang YJ, Du ZS, Wang XJ, et al. Signal transducer and activator of transcription 3 promotes the Warburg effect possibly by inducing pyruvate kinase M2 phosphorylation in liver precancerous lesions. World J Gastroenterol. 2019;25:1936–49.PubMedPubMedCentralCrossRef
152.
153.
Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, et al. JAK/STAT3-regulated fatty acid beta-oxidation is critical for breast Cancer stem cell self-renewal and Chemoresistance. Cell Metab. 2018;27(136–150):e135.
154.
Li J, Zhao S, Zhou X, Zhang T, Zhao L, Miao P, et al. Inhibition of lipolysis by mercaptoacetate and etomoxir specifically sensitize drug-resistant lung adenocarcinoma cell to paclitaxel. PLoS One. 2013;8:e74623.PubMedPubMedCentralCrossRef
155.
He W, Liang B, Wang C, Li S, Zhao Y, Huang Q, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019;38:4637–54.PubMedPubMedCentralCrossRef
156.
Gao P, Wang LL, Liu J, Dong F, Song W, Liao L, et al. Dihydroartemisinin inhibits endothelial cell tube formation by suppression of the STAT3 signaling pathway. Life Sci. 2020;242:117221.PubMedCrossRef
157.
Menendez JA, Lupu R. Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin Ther Targets. 2017;21:1001–16.PubMedCrossRef
158.
Yu C, Niu X, Du Y, Chen Y, Liu X, Xu L, et al. IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment. Cancer Immunol Immunother. 2020;69:115–26.PubMedCrossRef
159.
160.
Chen J, Yue J, Liu Y, Liu J, Jiao K, Teng M, et al. Blocking of STAT-3/SREBP1-mediated glucose-lipid metabolism is involved in dietary phytoestrogen-inhibited ovariectomized-induced body weight gain in rats. J Nutr Biochem. 2018;61:17–23.PubMedCrossRef
161.
Su T, Huang C, Yang C, Jiang T, Su J, Chen M, et al. Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity. Pharmacol Res. 2020;152:104586.PubMedCrossRef
162.
Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Attolini CS, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541:41–5.PubMedCrossRef
163.
Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014;10:728.PubMedPubMedCentralCrossRef
164.
165.
Jin W. Role of JAK/STAT3 signaling in the regulation of metastasis, the transition of Cancer stem cells, and Chemoresistance of Cancer by epithelial-mesenchymal transition. Cells. 2020;9.
166.
Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 2011;9:50–63.PubMedCrossRef
167.
You H, Ding W, Rountree CB. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology (Baltimore, Md). 2010;51:1635–44.PubMedCrossRef
168.
169.
Yang J, Liao D, Chen C, Liu Y, Chuang TH, Xiang R, et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/sox-2 signaling pathway. Stem Cells. 2013;31:248–58.PubMedCrossRef
170.
Valeta-Magara A, Gadi A, Volta V, Walters B, Arju R, Giashuddin S, et al. Inflammatory breast Cancer promotes development of M2 tumor-associated macrophages and Cancer mesenchymal cells through a complex chemokine network. Cancer Res. 2019;79:3360–71.PubMedPubMedCentralCrossRef
171.
Zhao C, Li H, Lin HJ, Yang S, Lin J, Liang G. Feedback activation of STAT3 as a Cancer drug-resistance mechanism. Trends Pharmacol Sci. 2016;37:47–61.PubMedCrossRef
172.
173.
Zhao Q, Huang L, Qin G, Qiao Y, Ren F, Shen C, et al. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Lett. 2021;518:35–48.PubMedCrossRef
174.
Tao L, Huang G, Wang R, Pan Y, He Z, Chu X, et al. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway. Sci Rep. 2016;6:38408.PubMedPubMedCentralCrossRef
175.
Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26:207–21.PubMedCrossRef
176.
Chua PJ, Lim JP, Guo TT, Khanna P, Hu Q, Bay BH, et al. Y-box binding protein-1 and STAT3 independently regulate ATP-binding cassette transporters in the chemoresistance of gastric cancer cells. Int J Oncol. 2018;53:2579–89.PubMed
177.
Zhang X, Sai B, Wang F, Wang L, Wang Y, Zheng L, et al. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. Mol Cancer. 2019;18:40.PubMedPubMedCentralCrossRef
178.
Zhang Q, Liu R-X, Chan K-W, Hu J, Zhang J, Wei L, et al. Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells. J Exp Clin Cancer Res. 2019;38:1–14.CrossRef
179.
Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, et al. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018;7:e1412909.PubMedPubMedCentralCrossRef
180.
Chuang HY, Su YK, Liu HW, Chen CH, Chiu SC, Cho DY, et al. Preclinical evidence of STAT3 inhibitor Pacritinib overcoming Temozolomide resistance via downregulating miR-21-enriched Exosomes from M2 glioblastoma-associated macrophages. J Clin Med. 2019;8.
181.
Timofeeva OA, Tarasova NI, Zhang X, Chasovskikh S, Cheema AK, Wang H, et al. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A. 2013;110:1267–72.PubMedPubMedCentralCrossRef
182.
La Sala G, Michiels C, Kukenshoner T, Brandstoetter T, Maurer B, Koide A, et al. Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains. Nat Commun. 2020;11:4115.PubMedPubMedCentralCrossRef
183.
Huang W, Dong Z, Chen Y, Wang F, Wang CJ, Peng H, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene. 2016;35:783–92.PubMedCrossRef
184.
Don-Doncow N, Escobar Z, Johansson M, Kjellstrom S, Garcia V, Munoz E, et al. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. J Biol Chem. 2014;289:15969–78.PubMedPubMedCentralCrossRef
185.
Hellsten R, Johansson M, Dahlman A, Dizeyi N, Sterner O, Bjartell A. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate. 2008;68:269–80.PubMedCrossRef
186.
Ko H, Lee JH, Kim HS, Kim T, Han YT, Suh YG, et al. Novel Galiellalactone analogues can target STAT3 phosphorylation and cause apoptosis in triple-negative breast Cancer. Biomolecules. 2019;9.
187.
Escobar Z, Bjartell A, Canesin G, Evans-Axelsson S, Sterner O, Hellsten R, et al. Preclinical characterization of 3beta-(N-acetyl l-cysteine methyl ester)-2abeta,3-dihydrogaliellalactone (GPA512), a prodrug of a direct STAT3 inhibitor for the treatment of prostate Cancer. J Med Chem. 2016;59:4551–62.PubMedCrossRef
188.
Jiang X, Wu M, Xu Z, Wang H, Wang H, Yu X, et al. HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer. Cancer Manag Res. 2018;10:6857–67.PubMedPubMedCentralCrossRef
189.
Gu M, Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res. 2007;67:3483–91.PubMedCrossRef
190.
Byun HJ, Darvin P, Kang DY, Sp N, Joung YH, Park JH, et al. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells. Oncol Rep. 2017;37:3270–8.PubMedCrossRef
191.
Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther. 2010;9:1169–79.PubMedPubMedCentralCrossRef
192.
Huang W, Liu Y, Wang J, Yuan X, Jin HW, Zhang LR, et al. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis. Eur J Med Chem. 2018;157:887–97.PubMedCrossRef
193.
Son DJ, Zheng J, Jung YY, Hwang CJ, Lee HP, Woo JR, et al. MMPP attenuates non-small cell lung Cancer growth by inhibiting the STAT3 DNA-binding activity via direct binding to the STAT3 DNA-binding domain. Theranostics. 2017;7:4632–42.PubMedPubMedCentralCrossRef
194.
Wei N, Li J, Fang C, Chang J, Xirou V, Syrigos NK, et al. Targeting colon cancer with the novel STAT3 inhibitor bruceantinol. Oncogene. 2019;38:1676–87.PubMedCrossRef
195.
Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res : MCR. 2004;2:170–82.PubMedCrossRef
196.
Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003;100:4138–43.PubMedPubMedCentralCrossRef
197.
Liang M, Zhan F, Zhao J, Li Q, Wuyang J, Mu G, et al. CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3. BMC Cancer. 2016;16:504.PubMedPubMedCentralCrossRef
198.
Koseki T, Suehiro N, Masuda Y, Miyoshi N, Muraoka D, Ogo N, et al. Discovery of a new STAT3 inhibitor acting on the linker domain. Biol Pharm Bull. 2019;42:792–800.PubMedCrossRef
199.
Kim BH, Lee H, Park CG, Jeong AJ, Lee SH, Noh KH, et al. STAT3 inhibitor ODZ10117 suppresses glioblastoma malignancy and prolongs survival in a glioblastoma xenograft model. Cells. 2020;9.
200.
Chen H, Bian A, Yang LF, Yin X, Wang J, Ti C, et al. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression. Oncogene. 2021;40:1440–57.PubMedPubMedCentralCrossRef
201.
Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell. 2019;36(498–511):e417.
202.
Adachi M, Cui C, Dodge CT, Bhayani MK, Lai SY. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol. 2012;48:1220–6.PubMedPubMedCentralCrossRef
203.
Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007;104:7391–6.PubMedPubMedCentralCrossRef
204.
Gurbuz V, Konac E, Varol N, Yilmaz A, Gurocak S, Menevse S, et al. Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro. Oncol Lett. 2014;7:755–63.PubMedPubMedCentralCrossRef
205.
Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, et al. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res. 2013;73:1922–33.PubMedPubMedCentralCrossRef
206.
Soleimani AH, Garg SM, Paiva IM, Vakili MR, Alshareef A, Huang YH, et al. Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma. Drug Deliv Transl Res. 2017;7:571–81.PubMedCrossRef
207.
Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, Pandit B, et al. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett. 2008;18:391–5.PubMedCrossRef
208.
Fuh B, Sobo M, Cen L, Josiah D, Hutzen B, Cisek K, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer. 2009;100:106–12.PubMedPubMedCentralCrossRef
209.
210.
Zhao C, Wang W, Yu W, Jou D, Wang Y, Ma H, et al. A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells. Oncotarget. 2016;7:12917–26.PubMedPubMedCentralCrossRef
211.
Zhao W, Jaganathan S, Turkson J. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J Biol Chem. 2010;285:35855–65.PubMedPubMedCentralCrossRef
212.
Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276:45443–55.PubMedCrossRef
213.
Chen J, Bai L, Bernard D, Nikolovska-Coleska Z, Gomez C, Zhang J, et al. Structure-based Design of Conformationally Constrained, cell-permeable STAT3 inhibitors. ACS Med Chem Lett. 2010;1:85–9.PubMedPubMedCentralCrossRef
214.
Auzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, et al. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J Exp Ther Oncol. 2012;10:155.PubMedPubMedCentral
215.
Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, et al. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem. 2011;54:3549–63.PubMedPubMedCentralCrossRef
216.
Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res. 2004;64:6603–9.PubMedCrossRef
217.
Li S, Zhang W, Yang Y, Ma T, Guo J, Wang S, et al. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein. Eur J Med Chem. 2016;124:1006–18.PubMedCrossRef
218.
Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM. STAT3 cyclic decoy demonstrates robust antitumor effects in non-small cell lung Cancer. Mol Cancer Ther. 2018;17:1917–26.PubMedPubMedCentralCrossRef
219.
Herrmann A, Priceman SJ, Swiderski P, Kujawski M, Xin H, Cherryholmes GA, et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest. 2014;124:2977–87.PubMedPubMedCentralCrossRef
220.
Kampan NC, Xiang SD, McNally OM, Stephens AN, Quinn MA, Plebanski M. Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in Cancer: challenges and opportunities. Curr Med Chem. 2018;25:4785–806.PubMedCrossRef
221.
Goumas FA, Holmer R, Egberts JH, Gontarewicz A, Heneweer C, Geisen U, et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int J Cancer. 2015;137:1035–46.PubMedCrossRef
222.
Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A. 2005;102:5998–6003.PubMedPubMedCentralCrossRef
223.
Lu X, Zhang T, Zhu SJ, Xun Q, Tong L, Hu X, et al. Discovery of JND3229 as a new EGFR(C797S) mutant inhibitor with in vivo Monodrug efficacy. ACS Med Chem Lett. 2018;9:1123–7.PubMedPubMedCentralCrossRef
224.
Ge H, Liu H, Fu Z, Sun Z. Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma. J Int Med Res. 2012;40:455–66.PubMedCrossRef
225.
Cha HJ, Choi JH, Park IC, Kim CH, An SK, Kim TJ, et al. Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells. Int J Oncol. 2017;50:1279–88.PubMedCrossRef
226.
Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia. 2010;12:28–38.PubMedPubMedCentralCrossRef
227.
Mohan CD, Bharathkumar H, Bulusu KC, Pandey V, Rangappa S, Fuchs JE, et al. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. J Biol Chem. 2014;289:34296–307.PubMedPubMedCentralCrossRef
228.
Zhang Y, Li J, Zhong H, Xiao X, Wang Z, Cheng Z, et al. The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis. Cell Death Discov. 2021;7:268.PubMedPubMedCentralCrossRef
229.
Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13:311–20.PubMedCrossRef
230.
Hu M, Xu C, Yang C, Zuo H, Chen C, Zhang D, et al. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms. J Exp Clin Cancer Res. 2019;38:1–12.CrossRef
231.
He W, Zhu Y, Mu R, Xu J, Zhang X, Wang C, et al. A Jak2-selective inhibitor potently reverses the immune suppression by modulating the tumor microenvironment for cancer immunotherapy. Biochem Pharmacol. 2017;145:132–46.PubMedCrossRef
232.
Purandare AV, McDevitt TM, Wan H, You D, Penhallow B, Han X, et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012;26:280–8.PubMedCrossRef
233.
Jia X, Huang C, Hu Y, Wu Q, Liu F, Nie W, et al. Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res : CR. 2021;40:105.PubMedPubMedCentralCrossRef
234.
Akahane K, Li Z, Etchin J, Berezovskaya A, Gjini E, Masse CE, et al. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2017;177:271–82.PubMedPubMedCentralCrossRef
235.
Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, et al. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3. Cancer Lett. 2014;349:136–43.PubMedCrossRef
236.
Chung SY, Chen YH, Lin PR, Chao TC, Su JC, Shiau CW, et al. Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells. Cell Death Discov. 2018;4:25.PubMedCrossRef
237.
Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, et al. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody. Br J Pharmacol. 2013;168:658–72.PubMedPubMedCentralCrossRef
238.
Zgheib C, Zouein FA, Chidiac R, Kurdi M, Booz GW. Calyculin a reveals serine/threonine phosphatase protein phosphatase 1 as a regulatory nodal point in canonical signal transducer and activator of transcription 3 signaling of human microvascular endothelial cells. J Interf Cytokine Res. 2012;32:87–94.CrossRef
239.
Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, et al. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Sci. 2015;106:896–901.PubMedPubMedCentralCrossRef
240.
Wong AL, Soo RA, Tan DS, Lee SC, Lim JS, Marban PC, et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol : Off J Eur Soc Med Oncol. 2015;26:998–1005.CrossRef
241.
Bendell JC, Hong DS, Burris HA 3rd, Naing A, Jones SF, Falchook G, et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014;74:125–30.PubMedCrossRef
242.
Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, et al. Phase I study of OPB-31121, an Oral STAT3 inhibitor, in patients with advanced solid tumors. Cancer Res Treat. 2015;47:607–15.PubMedPubMedCentralCrossRef
243.
Dai X, Karol MD, Hitron M, Hard ML, Blanchard JE, Eraut N, et al. Mass balance and pharmacokinetics of an oral dose of (14) C-napabucasin in healthy adult male subjects. Pharmacol Res Perspect. 2021;9:e00722.PubMedPubMedCentralCrossRef
244.
Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, et al. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:263–70.PubMedCrossRef
245.
Sonbol MB, Ahn DH, Goldstein D, Okusaka T, Tabernero J, Macarulla T, et al. CanStem111P trial: a phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Future Oncol. 2019;15:1295–302.PubMedCrossRef
246.
Kawazoe A, Kuboki Y, Shinozaki E, Hara H, Nishina T, Komatsu Y, et al. Multicenter phase I/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP trial). Clin Cancer Res. 2020;26:5887–94.PubMedCrossRef
247.
Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018;6:119.PubMedPubMedCentralCrossRef
248.
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;7:314ra185.PubMedPubMedCentralCrossRef
249.
Brown JR, Walker SR, Heppler LN, Tyekucheva S, Nelson EA, Klitgaard J, et al. Targeting constitutively active STAT3 in chronic lymphocytic leukemia: a clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2021;96:E95–8.PubMedPubMedCentralCrossRef
250.
Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, et al. Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma. Cancer Res Treat. 2019;51:510–8.PubMedCrossRef
251.
Rossi JF, Negrier S, James ND, Kocak I, Hawkins R, Davis H, et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010;103:1154–62.PubMedPubMedCentralCrossRef
252.
Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res : Off J Am Assoc Cancer Res. 2014;20:2192–204.CrossRef
253.
Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;161:357–66.PubMedPubMedCentralCrossRef
254.
Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van Veldhuizen Jr PJ, et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010;16:3028–34.PubMedPubMedCentralCrossRef
255.
Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2012;48:85–93.PubMedCrossRef
256.
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann Oncol : Off J Eur Soc Med Oncol. 2015;26:2141–9.CrossRef
257.
Baird K, Glod J, Steinberg SM, Reinke D, Pressey JG, Mascarenhas L, et al. Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. Sarcoma. 2020;2020:7935475.PubMedPubMedCentralCrossRef
258.
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus Imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol : Off J Am Soc Clin Oncol. 2018;36:231–7.CrossRef
259.
Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012;118:63–71.PubMedCrossRef
260.
Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013;14:1307–16.PubMedPubMedCentralCrossRef
261.
Kim DW, Saussele S, Williams LA, Mohamed H, Rong Y, Zyczynski T, et al. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol. 2018;97:1357–67.PubMedPubMedCentralCrossRef
262.
Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol. 2009;10:581–8.PubMedCrossRef
263.
Bono P, Massard C, Peltola KJ, Azaro A, Italiano A, Kristeleit RS, et al. Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. ESMO Open. 2020;5:e001081.PubMedPubMedCentralCrossRef
264.
Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, et al. Phase I study of OM-174, a lipid a analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013;13:172.PubMedPubMedCentralCrossRef
265.
Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti–insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007;13:5834–40.PubMedCrossRef
266.
Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012;119:4614–8.PubMedPubMedCentralCrossRef
267.
Barbie DA, Spira A, Kelly K, Humeniuk R, Kawashima J, Kong S, et al. Phase 1B study of Momelotinib combined with Trametinib in metastatic, Kirsten rat sarcoma viral oncogene homolog-mutated non-small-cell lung Cancer after platinum-based chemotherapy treatment failure. Clin Lung Cancer. 2018;19:e853–9.PubMedPubMedCentralCrossRef
268.
Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117–27.PubMedPubMedCentralCrossRef
269.
Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and efficacy of Fedratinib in patients with primary or secondary Myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1:643–51.PubMedCrossRef
270.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4:e317–24.PubMedPubMedCentralCrossRef
271.
Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016;9:137.PubMedPubMedCentralCrossRef
272.
Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, et al. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. Leuk Res. 2018;71:82–8.PubMedCrossRef
273.
Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010;115:1131–6.PubMedPubMedCentralCrossRef
274.
Timofeeva OA, Gaponenko V, Lockett SJ, Tarasov SG, Jiang S, Michejda CJ, et al. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biol. 2007;2:799–809.PubMedCrossRef
275.
Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015;112:1839–44.PubMedPubMedCentralCrossRef
276.
Kawazoe A, Kuboki Y, Bando H, Fukuoka S, Kojima T, Naito Y, et al. Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020;85:855–62.PubMedPubMedCentralCrossRef
277.
Mertens C, Haripal B, Klinge S, Darnell JE. Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity. Proc Natl Acad Sci U S A. 2015;112:14811–6.PubMedPubMedCentralCrossRef
278.
Maryam A, Mehmood T, Yan Q, Li Y, Khan M, Ma T. Proscillaridin a promotes oxidative stress and ER stress, inhibits STAT3 activation, and induces apoptosis in A549 lung adenocarcinoma cells. Oxidative Med Cell Longev. 2018;2018:3853409.CrossRef
279.
Maryam A, Mehmood T, Zhang H, Li Y, Khan M, Ma T. Alantolactone induces apoptosis, promotes STAT3 glutathionylation and enhances chemosensitivity of A549 lung adenocarcinoma cells to doxorubicin via oxidative stress. Sci Rep. 2017;7:6242.PubMedPubMedCentralCrossRef
280.
Khan MW, Saadalla A, Ewida AH, Al-Katranji K, Al-Saoudi G, Giaccone ZT, et al. The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer. Cancer Immunol Immunother. 2018;67:13–23.PubMedCrossRef
281.
Brambilla L, Lahiri T, Cammer M, Levy DE. STAT3 inhibitor OPB-51602 is cytotoxic to tumor cells through inhibition of complex I and ROS induction. Iscience. 2020;23.
282.
Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, et al. A first-in-human phase I study of OPB-111077, a small-molecule STAT3 and oxidative phosphorylation inhibitor, in patients with advanced cancers. Oncologist. 2018;23:658-e672.PubMedPubMedCentralCrossRef
283.
Luo D, Fraga-Lauhirat M, Millings J, Ho C, Villarreal EM, Fletchinger TC, et al. Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation. Carcinogenesis. 2019;40:1480–91.PubMedPubMedCentralCrossRef
284.
Jia X, Huang C, Hu Y, Wu Q, Liu F, Nie W, et al. Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res. 2021;40:1–15.CrossRef
285.
Johari B, Rahmati M, Nasehi L, Mortazavi Y, Faghfoori MH, Rezaeejam H. Evaluation of STAT3 decoy oligodeoxynucleotides’ synergistic effects on radiation and/or chemotherapy in metastatic breast cancer cell line. Cell Biol Int. 2020;44:2499–511.PubMedCrossRef
286.
Moreira D, Sampath S, Won H, White SV, Su YL, Alcantara M, et al. Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity. J Clin Invest. 2021;131.
287.
Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh MY, et al. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Mol Cancer. 2015;14:100.PubMedPubMedCentralCrossRef
288.
Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY, Chen YB. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor. Oncotarget. 2015;6:14329–43.PubMedPubMedCentralCrossRef
289.
Li G, Zhao L, Li W, Fan K, Qian W, Hou S, et al. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget. 2014;5:8317–29.PubMedPubMedCentralCrossRef
290.
Ashizawa T, Iizuka A, Maeda C, Tanaka E, Kondou R, Miyata H, et al. Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status. Immunol Lett. 2019;216:43–50.PubMedCrossRef
291.
Datta J, Dai X, Bianchi A, De Castro SI, Mehra S, Garrido VT, et al. Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for Cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic Cancer. Gastroenterology. 2022;163:1593–612.PubMedCrossRef
292.
Witt K, Evans-Axelsson S, Lundqvist A, Johansson M, Bjartell A, Hellsten R. Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. Cancer Immunol Immunother. 2021;70:3155–66.PubMedPubMedCentralCrossRef
293.
Huang L, Xu Y, Fang J, Liu W, Chen J, Liu Z, et al. Targeting STAT3 abrogates Tim-3 upregulation of adaptive resistance to PD-1 blockade on regulatory T cells of melanoma. Front Immunol. 2021;12:654749.PubMedPubMedCentralCrossRef
294.
Hubbard JM, Grothey A. Napabucasin: An update on the first-in-class Cancer Stemness inhibitor. Drugs. 2017;77:1091–103.PubMedCrossRef
295.
Zhang L, Huang J, Chen X, Pan C, He Y, Su R, et al. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response. J Immunother Cancer. 2021;9.
296.
Ngamcherdtrakul W, Reda M, Nelson MA, Wang R, Zaidan HY, Bejan DS, et al. In situ tumor vaccination with nanoparticle co-delivering CpG and STAT3 siRNA to effectively induce whole-body antitumor immune response. Adv Mater. 2021;33:e2100628.PubMedPubMedCentralCrossRef
297.
Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21:141–62.PubMedCrossRef
298.
Mohamed E, Al-Khami AA, Rodriguez PC. The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates. Cell Mol Immunol. 2018;15:421–7.PubMedPubMedCentralCrossRef
299.
Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999;59:5059–63.PubMed
300.
Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51.PubMedCrossRef
301.
Ashrafizadeh M, Zarrabi A, Hushmandi K, Hashemi F, Rahmani Moghadam E, Raei M, et al. Progress in natural compounds/siRNA co-delivery employing Nanovehicles for Cancer therapy. ACS Comb Sci. 2020;22:669–700.PubMedPubMedCentralCrossRef
Metadata
Title
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
Authors
Yamei Hu
Zigang Dong
Kangdong Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-024-02949-5

Other articles of this Issue 1/2024

Journal of Experimental & Clinical Cancer Research 1/2024 Go to the issue

Research

Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside

Review

From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review

Correction

Correction: Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/ GPX4 expression

Research

Analysis of the effect of CCR7 on the microenvironment of mouse oral squamous cell carcinoma by single-cell RNA sequencing technology

Research

The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions

Research

GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the cAMP/PKA/CREB pathway to promote glioma progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits